BackTable / Urology / Contributor
Dr. Siamak Daneshmand
Dr. Siamak Daneshmand is a professor of urology and director of clinical research at USC in California.
Listen to Dr. Siamak Daneshmand on the BackTable Urology Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Siamak Daneshmand and get practical advice on how to build your practice by listening to the BackTable Urology Podcast.
Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.
Stay Up To Date
About Dr. Siamak Daneshmand
Dr. Sia Daneshmand is currently Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles. Dr. Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. His main interests include bladder cancer, advanced kidney cancer and testicular cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on testicular cancer as well as non-muscle invasive bladder cancer. He was recently elected chair of the SUO Clinical Trials Consortium (SUO-CTC) bladder organ committee and serves as the Secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 11 consecutive years. He is an active member of the Society of Urologic Oncology, has presented over 400 abstracts at scientific meetings and has authored over 300 peer-reviewed articles, reviews, and book chapters.
Learn more by visiting Dr. Siamak Daneshmand's practice:
Podcasts Featuring Dr. Siamak Daneshmand
We talk with Dr. Siamak Daneshmand, Director of Urologic Oncology at USC Institute Of Urology, about the management of muscle-invasive bladder cancer. Listen to the full episode to learn tips for successful transurethral resections of bladder tumor (TURBT) and cystectomies, using imaging to stage bladder cancers, deciding between a cystectomy vs. trimodality therapy (TMT), and comparisons between neobladder procedures and urinary diversions.
Thank you for listening! If you have a question for Dr. Siamak Daneshmand about a topic discussed on the BackTable Urology Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.